Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a San Diego-based clinical-stage biotech company specializing in the development of safer prescription drugs using its proprietary technology platforms. The company focuses on creating new, tamper-proof opioids that aim to reduce drug abuse and prevent overdoses. Ensysce leverages its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms to develop innovative pain relief options with a lower risk of misuse.
The company’s core projects include two key drug platforms: the TAAP technology, which activates upon ingestion to release pain medication, and the MPAR technology, designed to prevent overdose by inhibiting further release of the drug when excess doses are consumed. These platforms are supported by global intellectual property protection, ensuring a wide array of prescription drug compositions.
Recent milestones include the FDA’s Breakthrough Therapy designation for PF614-MPAR, a combination product designed to provide overdose protection alongside effective pain relief. This designation accelerates the drug’s development and review process, highlighting its potential to offer substantial improvements over existing therapies. Ensysce’s lead candidate, PF614, is currently in Phase 3 clinical development, having demonstrated efficacy and safety in previous trials.
In terms of financial health, Ensysce has shown stability, with recent funding from federal grants and warrant exercises supporting ongoing research and development. The company's collaboration with Quotient Sciences aims to further optimize their PF614-MPAR drug product, enhancing its effectiveness and safety profile.
Ensysce is also expanding its product pipeline to address opioid use disorder (OUD) with PF9001, a TAAP-based candidate that has shown promise in reducing cardiovascular side effects compared to traditional treatments. Supported by a multi-year HEAL grant from the NIH and NIDA, this candidate is poised to enter human clinical studies within the next 12 to 18 months.
For more detailed information about Ensysce Biosciences, Inc. and its innovative projects, please visit www.ensysce.com.
Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced that CEO Dr. Lynn Kirkpatrick will speak at a webinar titled ‘Strategies for Achieving Regulatory Milestones Faster’ on April 19, 2023, at 11:30 am ET. The webinar will highlight the integration of Quotient Sciences in developing PF614-MPAR, a novel opioid therapeutic for chronic pain designed to minimize abuse and overdose risks. Dr. Kirkpatrick will address the potential impact of MPAR on future pain management and share insights on Ensysce's collaboration with Quotient. Ensysce is committed to developing safer prescription drugs through innovative technologies like TAAP and MPAR, which are underpinned by substantial intellectual property protections.
Ensysce Biosciences, a clinical-stage biotech company focused on enhancing drug safety, announced the availability of an updated investor presentation on its website.
The company will host a corporate update conference call today, April 11, 2023, at 11:00 AM ET. Investors can dial in using the provided numbers and access a webcast link. A playback option will be available until May 9, 2023.
Ensysce employs proprietary technologies like TAAP and MPAR to develop tamper-proof medications aimed at reducing drug abuse risks.
Forward-looking statements indicate uncertainties in clinical success and regulatory approvals, emphasizing risks in ongoing trials and potential financial constraints.
Ensysce Biosciences (NASDAQ:ENSC) has announced positive results from a study evaluating the oral human abuse potential of its drug PF614. The study demonstrated that PF614 had significantly lower 'Drug Liking' scores compared to oxycodone at various doses, indicating reduced abuse potential. Key endpoints were met, showing PF614's lower scores at p<0.0001 and p=0.0025 for 'Overall Drug Liking'. This success paves the way for discussions with the FDA to initiate phase 3 trials. CEO Lynn Kirkpatrick expressed confidence in PF614's ability to address severe pain while minimizing abuse risks.
FAQ
What is the current stock price of Ensysce Biosciences (ENSC)?
What is the market cap of Ensysce Biosciences (ENSC)?
What is Ensysce Biosciences, Inc.?
What technologies does Ensysce use in its drug development?
What are the core products in Ensysce’s development pipeline?
What recent achievements have Ensysce made?
What is the significance of FDA Breakthrough Therapy designation?
How is Ensysce addressing the opioid epidemic?
What financial strategies support Ensysce’s operations?
What partnerships has Ensysce formed to advance its drug development?
What future projects is Ensysce Biosciences involved in?